Last updated: February 21, 2026
What is the Drug Identified by NDC 70752-0139?
The National Drug Code (NDC) 70752-0139 corresponds to Alectinib (Alecensa), produced by Genentech (a Roche subsidiary). Alectinib is an oral ALK inhibitor used primarily for treating ALK-positive non-small cell lung cancer (NSCLC). It gained FDA approval in 2017 and is considered a second-line therapy after crizotinib failure.
Market Landscape
Market Size and Growth Potential
- Current Market Size: The global ALK inhibitor market was valued at approximately USD 1.8 billion in 2022. Alectinib accounts for an estimated 45-55% of this segment, translating to roughly USD 800-990 million.
- Growth Rate: The market for ALK inhibitors is projected to grow at a compound annual growth rate (CAGR) of 12-15% through 2030, driven by increased diagnosis and adoption of targeted therapies.
Competitive Position
| Drug Name |
Market Share |
Key Features |
Price (per treatment cycle) |
Regulatory Status |
| Alectinib |
~50% |
High efficacy, CNS penetration |
USD 12,000 - 15,000 |
FDA approved, global markets |
| Crizotinib |
~30% |
First-generation ALK inhibitor |
USD 10,000 - 13,000 |
FDA approved, generic versions exist |
| Brigatinib, Lorlatinib |
Remaining |
Next-generation ALK inhibitors |
USD 14,000 - 20,000 |
FDA approved, newer entries |
Prescription Trends
- The number of diagnosed ALK-positive NSCLC cases in the U.S. is around 20,000 annually.
- Approximately 60% of these patients receive targeted therapy, with Alectinib capturing a significant share.
- Prescriptions increased by 22% YoY since 2018, reflecting expanded adoption and earlier diagnosis.
Price Projections
Factors Affecting Price Dynamics
- Patent Status: Patent expiry for Alecensa remains until at least 2027, potentially enabling biosimilar entry.
- Market Competition: Introduction of biosimilars or generics would compress prices.
- Regulatory and reimbursement policies: Variations influence net prices; US payers negotiate discounts.
- Manufacturing costs and R&D investments: Slightly decrease overall margins but do not significantly influence list prices in the short term.
Short-term (2023-2025)
- List price is expected to remain stable, approximately USD 12,000 - 15,000 per cycle.
- Rebate and discounting practices could reduce patient out-of-pocket costs by 20-25%.
Medium-term (2026-2030)
- Patent expiration anticipated around 2027 could lead to biosimilar entry.
- Biosimilar consideration may trigger a price decrease of 20-35%, depending on market uptake.
- Prices for biosimilars might start at 50-70% of the originator, approximately USD 6,000 - 10,000 per cycle.
Long-term (Post-2030)
- With increased biosimilar competition, prices could stabilize at or below USD 6,000 per cycle.
- Market shares of biosimilars could reach 60% or higher, depending on regulatory and payer acceptance.
Pricing in Different Markets
| Region |
Current Price Range (USD) |
Factors Influencing Price |
| United States |
12,000 - 15,000 |
Reimbursement negotiations, rebates |
| European Union |
9,000 - 13,000 |
Price controls, health technology assessments |
| Japan |
1,200,000 - 1,500,000 JPY |
Price regulation, aging population |
| Emerging Markets |
8,000 - 10,000 |
Limited access, regulatory hurdles |
Key Drivers and Risks
- Drug efficacy and safety profile support sustained demand.
- Patent expirations pose a risk of price erosion.
- Regulatory changes could introduce pricing constraints.
- Market entry of biosimilars will influence price dynamics significantly post-2027.
Key Takeaways
- The current price for NDC 70752-0139 (Alecensa) is around USD 12,000 - 15,000 per cycle.
- The global ALK inhibitor market exceeds USD 1.8 billion with CAGR of around 13%.
- Competitive pressures, especially from biosimilars post-2027, could reduce prices by up to 35%.
- Prescription volumes are increasing with expanded indications, supporting revenue stability in the near term.
- Regional pricing varies considerably based on reimbursement policies and market maturity.
FAQs
Q1: What are the main competitive advantages of Alectinib?
A1:* High efficacy, CNS penetration, and a favorable safety profile. It is preferred as a first-line therapy in ALK-positive NSCLC.
Q2: How soon could biosimilar versions be available?
A2:* Likely post-2027, following patent expiry. Biosimilar development and approvals could take 2-3 years after patent expiration.
Q3: What is the impact of regulatory policies on pricing?
A3:* Price controls and health technology assessments can reduce list prices, especially in Europe and emerging markets.
Q4: How do discounts and rebates affect actual expenditure?
A4:* Payers typically negotiate discounts, reducing effective prices by 20-25%.
Q5: What does future market expansion depend on?
A5:* Broader testing, early detection, regulatory approvals for new indications, and competitive biosimilar entry.
References
- MarketWatch. (2022). Global ALK inhibitors market size. Retrieved from https://www.marketwatch.com
- FDA. (2017). FDA approves Alecensa for ALK-positive NSCLC. https://www.fda.gov
- IQVIA. (2022). Prescription trends for ALK inhibitors. https://www.iqvia.com
- EvaluatePharma. (2022). Oncology drug market forecasts. https://www.evaluate.com
